Inflammatory low back pain-associated malignancies mimicking spondylarthritis.

Hematological malignancy Inflammatory low back pain Malignancy Solid tumors Spondylarthritis

Journal

Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469

Informations de publication

Date de publication:
17 Sep 2024
Historique:
received: 30 05 2024
accepted: 07 09 2024
revised: 15 08 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: aheadofprint

Résumé

Inflammatory low back pain (IBP) is a typical feature of spondylarthritis (SpA). IBP can be caused by infections, drugs, and different malignancies. Among cancers, hematologic malignancies and solid tumors can cause IBD either paraneoplastically or through metastasis. In this study, we aimed to present the demographic and clinical characteristics of our patients who presented with IBP in the last 10 years and whose final diagnosis was malignancy. Thirty-four patients who presented with inflammatory low back pain in the last 10 years and were diagnosed with malignancy as the final diagnosis were included in the study. Thirty-six patients, diagnosed as axial SpA, with similar age-sex ratio of 1:1 from each center were included as the control group. Hematologic malignancies were multiple myeloma, acute leukemia, and lymphoma in descending order. Solid tumors were breast cancer, lung cancer, bone tumors, prostate, colon, embryonal carcinoma, and malignancy of unknown primary. In malignancy-related low back pain, the hematologic/solid ratio was similar (18/16), the interval between symptom and diagnosis was shorter, and biomarkers' results such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum lactate dehydrogenase (LDH) levels were significantly higher than the control group. Malignancy-related low back pain differs from SpA patients with a more severe clinical picture, higher acute phase reactants levels, and higher LDH values. Malignancies must be kept in mind in the differential diagnosis, and in order to validate our findings, the results of larger case series are needed, especially in terms of causative malignancies. Key Points • In malignancy-related inflammatory low back pain, the hematologic/solid ratio was similar, the interval between symptom and diagnosis was shorter, and acute phase reactant levels and LDH levels were significantly higher. • Malignancy-related inflammatory low back pain differs from axial SpA patients with a more severe clinical picture, higher acute phase reactants levels, and higher LDH values. • Malignancies must be kept in mind in the differential diagnosis of axial SpA.

Identifiants

pubmed: 39285007
doi: 10.1007/s10067-024-07141-w
pii: 10.1007/s10067-024-07141-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Références

Hoy D, Brooks P, Blyth F, Buchbinder R (2010) The epidemiology of low back pain. Best Pract Res Clin Rheumatol 24:769–781
pubmed: 21665125
Rudwaleit M, van der Heijde D, Khan MA et al (2004) How to diagnose axial spondylarthritis early. Ann Rheum Dis 63:535–543
pubmed: 15082484 pmcid: 1754994
Salvadorini G, Bandinelli F, DelleSedie A et al (2012) Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol. 30(4):561–5
pubmed: 22510360
Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783
pubmed: 19297344
Kisacik B, Dag MS, Pehlivan Y et al (2014) Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis. Rheumatol Int 34(6):873–874. https://doi.org/10.1007/s00296-013-2777-1
pubmed: 23686219
Alkan S, Kayiran N, Zengin O et al (2015) Isotretinoin-induced spondyloarthropathy-related symptoms: a prospective study. J Rheumatol 42(11):2106–2109. https://doi.org/10.3899/jrheum.150013
pubmed: 26472411
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
pubmed: 33538338
Wedam SB, Beaver JA, Amiri-Kordestani L et al (2018) US Food and Drug Administration pooled analysis to assess the impact of bone-only metastatic breast cancer on clinical trial outcomes and radiographic assessments. J Clin Oncol 36:1225
pubmed: 29522361 pmcid: 5908220
Van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397:410
pubmed: 33516340
Bianchi G, Campanacci L, Ronchetti M, Donati D (2016) Electrochemotherapy in the treatment of bone metastases: a phase II trial. World J. Surg. 40:3088–94
pubmed: 27443372 pmcid: 5104781
Campanacci L, Cevolani L, De Terlizzi F et al (2022) Electrochemotherapy is effective in the treatment of bone metastases. Curr Oncol 29:1672–1682
pubmed: 35323339 pmcid: 8947745
Naschitz JE, Yeshurun D, Rosner I (1995) Rheumatic manifestations of occult cancer. Cancer 75:2954–2958
pubmed: 7773947
Downie A, Williams CM, Henschke N et al (2013) Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ 347:f7095. https://doi.org/10.1136/bmj.f7095
pubmed: 24335669 pmcid: 3898572
Henschke N, Williams C, Maher CG et al (2010) Red flags to screen for vertebral fracture in patients presenting with low-back pain. Cochrane Database of Systematic Reviews, Issue 8. https://doi.org/10.1002/14651858.cd008643 .
Liu G, Hao Y, Yang Q, Deng S (2020) The association of fecal microbiota in ankylosing spondylitis cases with C-reactive protein and erythrocyte sedimentation rate. Mediators Inflamm 2020:8884324
pubmed: 33204218 pmcid: 7666627
Kısacık B, Albayrak F, Balcı MA et al (2023) Paraneoplastic arthritis: a series of 92 cases. Rheumatology (Oxford). Published online September 21, 2023. https://doi.org/10.1093/rheumatology/kead500 .

Auteurs

Fatih Albayrak (F)

Department of Internal Medicine, Division of Rheumatology, Gaziantep City Hospital, Şehitkamil, Gaziantep, Turkey. drfalbayrak@yahoo.com.

Bünyamin Kısacık (B)

Department of Rheumatology, Faculty of Medicine, Gaziantep Sanko University, Şehitkamil, Gaziantep, Turkey.

İbrahim Gündüz (İ)

Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Fırat University, Elazığ, Turkey.

Özlem Kudaş (Ö)

Istanbul Physical Therapy Rehabilitation Training and Research Hospital, Istanbul, Turkey.

Emrah Koç (E)

Department of Internal Medicine, Division of Rheumatology, Adana City Hospital, Adana, Turkey.

Orhan Zengin (O)

Department of Internal Medicine, Division of Rheumatology, Gaziantep Medical Faculty Hospital, Gaziantep, Turkey.

Nagehan Dik Kutlu (ND)

Department of Internal Medicine, Division of Rheumatology, Uludağ Medical Faculty Hospital, Bursa, Turkey.

Mustafa Gür (M)

Department of Physical Therapy and Rehabilitation, Division of Rheumatology, Fethi Sekin City Hospital, Elazığ, Turkey.

Adem Küçük (A)

Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.

Menice Güler Şen (MG)

Department of Rheumatology, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey.

Şule Ketenci Ertaş (ŞK)

Department of Internal Medicine, Division of Rheumatology Acıbadem Hospital, Kayseri, Turkey.

Zeynel Abidin Akar (ZA)

Department of Physical Therapy and Rehabilitation, Division of Rheumatology, Dicle University Hospital, Diyarbakır, Turkey.

Süleyman Serdar Koca (SS)

Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Fırat University, Elazığ, Turkey.

Yavuz Pehlivan (Y)

Department of Internal Medicine, Division of Rheumatology, Uludağ Medical Faculty Hospital, Bursa, Turkey.

Classifications MeSH